| Literature DB >> 28704517 |
Chao Wang1, Ligen Zhang1, Weipeng Su1, Zhixiong Ying1, Jintian He1, Lili Zhang1, Xiang Zhong1, Tian Wang1.
Abstract
The objective of this study was to evaluate effects of zinc oxide nanoparticles (nano-ZnOs) as a substitute for colistin sulfate (CS) and/or zinc oxide (ZnO) on growth performance, serum enzymes, zinc deposition, intestinal morphology and epithelial barrier in weaned piglets. A total of 216 crossbred Duroc×(Landrace×Yorkshire) piglets weaned at 23 days were randomly assigned into 3 groups, which were fed with basal diets supplemented with 20 mg/kg CS (CS group), 20mg/kg CS+3000 mg/kg ZnO (CS+ZnO group), and 1200 mg/kg nano-ZnOs (nano-ZnO group) for 14 days. Results indicated that compared to CS group, supplementation of 1200 mg/kg nano-ZnOs (about 30 nm) significantly increased final body weight and average daily gain, and 3000 mg/kg ZnO plus colistin sulfate significantly increased average daily gain and decreased diarrhea rate in weaned piglets. There was no significant difference in growth performance and diarrhea rate between nano-ZnO and CS+ZnO groups. Supplementation of nano-ZnOs did not affect serum enzymes (glutamic oxalacetic transaminase, glutamic-pyruvic transaminase, and lactate dehydrogenase), but significantly increased plasma and tissue zinc concentrations (liver, tibia), improved intestinal morphology (increased duodenal and ileal villus length, crypt depth, and villus surface), enhanced mRNA expression of ZO-1 in ileal mucosa, and significantly decreased diamine oxidase activity in plasma, total aerobic bacterial population in MLN as compared to CS group. Effects of nano-ZnOs on serum enzymes, intestinal morphology, and mRNA expressions of tight junction were similar to those of high dietary ZnO plus colistin sulfate, while nano-ZnOs significantly reduced zinc concentrations of liver, tibia, and feces, and decreased total aerobic bacterial population in MLN as compared to CS+ZnO group. These results suggested that nano-ZnOs (1200 mg/kg) might be used as a substitute for colistin sulfate and high dietary ZnO in weaned piglets.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28704517 PMCID: PMC5509312 DOI: 10.1371/journal.pone.0181136
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Ingredients and chemical composition of basal diet (feed basis).
| Ingredients | % | Composition | |
|---|---|---|---|
| Corn | 54.50 | Digestible energy (Mcal/kg) | 3.44 |
| Soybean meal | 18.00 | Crude protein (%) | 21.15 |
| Soybean oil | 2.50 | Lysine (%) | 1.42 |
| Extruded soybean meal | 10.00 | Methionine (%) | 0.43 |
| Fish meal | 4.50 | Threonine (%) | 0.86 |
| Dried whey | 5.00 | Ca (%) | 0.87 |
| Glucose | 2 | P (%) | 0.71 |
| Dicalcium phosphate | 0.80 | Zn (mg/kg) | 164.97 |
| Limestone | 0.90 | ||
| Sodium chloride | 0.30 | ||
| Lysine | 0.35 | ||
| Methionine | 0.10 | ||
| Threonine | 0.05 | ||
| Vitamin-mineral premix | 1.0 |
a Supplied per kilogram diet as feed basis: Vitamin A, 5000 IU; Vitamin D3, 800 IU; Vitamin E, 30 IU; Vitamin K3, 1.0 mg; Biotin, 0.05mg; Folic acid, 0.3mg; Niacin, 10 mg; D-pantothenic acid, 10mg; Riboflavin, 3.6mg; Thiamine, 1.0mg; Pyridoxin, 1.5mg; Choline, 800mg; Zn (ZnSO4):120mg; Fe (FeSO4), 125mg; Cu (CuSO4·5H2O),15mg/kg; Mn (MnSO4·H2O), 10mg/kg; I (KI), 0.15 mg; Se (Na2SeO3), 0.2 mg; enramycin, 20 mg; chlortetracycline, 50 mg.
bFor the composition, digestible energy, lysine, methionine and threonine were calculated, while others were analyzed.
Primer sequences used in quantitative real time PCR assays.
| Gene | Accession No. | Sequence (5’ to 3’) | Size (bp) |
|---|---|---|---|
| Claudin-2 | NM_001161638.1 | 98 | |
| Occludin | NM_001163647.2 | 75 | |
| ZO-1 | XM_005659811.1 | 75 | |
| GAPDH | NM_001206359.1 | 98 | |
Fig 1TEM images of nano-ZnOs with low (A), middle (B) and high (C) magnification.
Effect of dietary nano-ZnOs on growth performance and diarrhea ratio in weaned piglets.
| Item | Treatments | |||
|---|---|---|---|---|
| CS | CS+ZnO | Nano-ZnO | ||
| Initial BW (kg) | 8.09±0.11 | 7.82±0.18 | 8.10±0.17 | 0.42 |
| Final BW (kg) | 10.68±0.13 | 11.11±0.05 | 11.35±0.19 | 0.03 |
| ADG (g) | 185.09±0.93 | 235.01±15.97 | 232.54±9.21 | 0.03 |
| ADFI (g) | 263.98±10.80 | 317.88±19.31 | 293.97±9.29 | 0.09 |
| F:G | 1.43±0.05 | 1.36±0.04 | 1.27±0.02 | 0.07 |
| Diarrhea rate | 9.31±1.63 | 3.84±0.74 | 5.70±0.74 | 0.04 |
a-b Means in a row with different superscripts were significantly different (P<0.05).
1Data were expressed as mean ± SE (n = 3).
2Treatments including: CS group: basal diet+20 mg/kg CS; CS+ZnO group: basal diet+20 mg/kg CS+3000 mg/kg ZnO;nano-ZnO group: basal diet+ 1200 mg/kg nano-ZnOs.
Effect of dietary nano-ZnOs on D-lactic acid, endotoxin and DAO in plasma.
| Item | Treatments | |||
|---|---|---|---|---|
| CS | CS+ZnO | Nano-ZnO | ||
| LDH(U/L) | 337.45±19.35 | 336.64±20.08 | 347.76±14.30 | 0.89 |
| GOT(U/L) | 26.44±2.97 | 26.75±1.12 | 33.83±4.47 | 0.21 |
| GPT(U/L) | 22.37±2.28 | 19.96±2.04 | 20.62±1.47 | 0.67 |
| D-lactic acid (μg/L) | 516.28±14.43 | 466.27±25.67 | 449.86±13.80 | 0.06 |
| Endotoxin(EU/L) | 0.42±0.01 | 0.38±0.01 | 0.34±0.03 | 0.05 |
| DAO(U/ml) | 11.57±0.49 | 9.17±0.19 | 8.71±0.59 | <0.01 |
a-b Means in a row with different superscripts were significantly different (P<0.05).
1Data were expressed as mean ± SE (n = 6).
2Treatments including: CS group: basal diet+20 mg/kg CS; CS+ZnO group: basal diet+20 mg/kg CS+3000 mg/kg ZnO;nano-ZnO group: basal diet+ 1200 mg/kg nano-ZnOs.
Effect of dietary nano-ZnOs on zinc concentration in plasma, liver, tibia and feces.
| Item | Treatments | |||
|---|---|---|---|---|
| CS | CS+ZnO | Nano-ZnO | ||
| Plasma (mg/L) | 1.56±0.09 | 3.43±0.18 | 3.37±0.19 | <0.001 |
| Tibia (mg/kg) | 138.77±6.37c | 272.99±17.19 | 212.04±12.90 | <0.001 |
| Liver (mg/kg) | 103.93±9.15c | 884.96±24.69 | 437.03±39.93 | <0.001 |
| Feces (g/kg) | 4.61±0.27c | 12.57±0.35 | 7.95±0.24 | <0.001 |
a-b Means in a row with different superscripts were significantly different (P<0.05).
1Data were expressed as mean ± SE. For zinc concentrations of tibia and liver, n = 6; For feces, n = 3.
2Treatments including: CS group: basal diet+20 mg/kg CS; CS+ZnO group: basal diet+20 mg/kg CS+3000 mg/kg ZnO;nano-ZnO group: basal diet+ 1200 mg/kg nano-ZnOs.
Fig 2Images of duodenal morphology in weaned piglets from CS (a), CS+ZnO (b) and nano-ZnO (c) groups.
Fig 3Images of ileal morphology in weaned piglets from CS (a), CS+ZnO (b) and nano-ZnO (c) groups.
Effect of dietary nano-ZnOs on intestinal morphology.
| Item | Treatments | |||
|---|---|---|---|---|
| CS | CS+ZnO | Nano-ZnO | ||
| Villus length (μm) | 279.68±4.48 | 307.72±4.70 | 317.36±7.85 | 0.001 |
| Crypt depth (μm) | 238.65±1.78 | 247.43±4.19 | 273.98±5.96 | <0.001 |
| Villi/crypt ratio | 1.17±0.02 | 1.25±0.03 | 1.16±0.01 | 0.02 |
| Villus width (μm) | 106.33±1.83 | 114.33±2.45 | 112.97±5.37 | 0.27 |
| Villus surface area (mm2) | 0.048±0.001 | 0.056±0.002 | 0.058±0.004 | 0.046 |
| Villus length (μm) | 212.86±12.03 | 240.19±3.86 | 251.99±7.46 | 0.02 |
| Crypt depth (μm) | 185.18±8.07 | 206.58±3.85 | 212.56±6.05 | 0.02 |
| Villi/crypt ratio | 1.15±0.03 | 1.16±0.02 | 1.19±0.01 | 0.46 |
| Villus width (μm) | 79.97±3.03 | 97.93±1.80 | 101.45±2.13 | <0.01 |
| Villus surface area (mm2) | 0.027±0.002 | 0.038±0.001 | 0.041±0.002 | <0.01 |
a-b Means in a row with different superscripts were significantly different (P<0.05).
1Data were expressed as mean ± SE (n = 6).
2Treatments including: CS group: basal diet+20 mg/kg CS; CS+ZnO group: basal diet+20 mg/kg CS+3000 mg/kg ZnO;nano-ZnO group: basal diet+ 1200 mg/kg nano-ZnOs.
Fig 4Effects of nano-ZnOs on total aerobic bacteria in MLN (A) and mRNA expressions of occludin, claudin-2, and ZO-1 in ileal mucosal (B). Data are expressed as mean± SE (n = 6). For the mRNA expression, data are normalized to the CS group. a-bMeans for the same parameter with different superscripts are significantly different (P<0.05).